Fulminant Hepatic Failure due to Nilutamide Hepatotoxicity

@article{Merwat2008FulminantHF,
  title={Fulminant Hepatic Failure due to Nilutamide Hepatotoxicity},
  author={Shehzad Nawaz Merwat and Wareef Kabbani and Douglas G. Adler},
  journal={Digestive Diseases and Sciences},
  year={2008},
  volume={54},
  pages={910-913}
}
We report the case of a 76-year-old man who developed fulminant hepatic failure after treatment with the antiandrogen nilutamide (Nilandron). Both reversible and fatal liver toxicity have been described in patients treated with flutamide, an analogue of nilutamide, although this has been less commonly described with nilutamide itself [1]. Our patient was prescribed nilutamide as part of combined androgen blockade. The patient’s liver biopsy was consistent with a drug-induced hepatitis. The… 
2 Citations

Current awareness: Pharmacoepidemiology and drug safety

  • Medicine
  • 2009
The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety in order to keep subscribers up‐to‐date with the latest developments in their field.

References

SHOWING 1-10 OF 17 REFERENCES

[Fatal fulminant hepatitis induced by nilutamide (Anandron)].

The first case of fatal fulminant hepatitis probably caused by nilutamide, a non steroidal antiandrogen derivative, is reported. Nilutamide administration had been continued for 6 days after the

Fatal and Nonfatal Hepatotoxicity Associated with Flutamide

This article summarizes reports submitted to the Food and Drug Administration of patients with hepatotoxicity that may have been caused by flutamide and reviews reports that originated in domestic patient care settings.

Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.

  • Mcleod
  • Medicine, Biology
    The oncologist
  • 1997
Bicalutamide appears to have some advantage over flutamide and nilutamide in terms of tolerability, and the reverse is true for hot flashes, which are a side effect of castration.

Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.

  • R. MigliariR. Scarpa E. Usai
  • Medicine, Biology
    Archivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell'Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences
  • 1991
Tolerability and efficacy of a combination therapy of a LHRH analogue (Buserelin) and a pure antiandrogen (Nilutamide) in a group of 15 patients with advanced prostate cancer (stage D) followed over a period of six months are evaluated.

Hépatite fulminante mortelle imputable au nilutamide (Anandron).

L'evolution rapidement fatale a pu etre precipitee par the prise conjointe de phenobarbital par la prise de nilutamide, un anti-androgene utilise dans le traitement des cancers de the prostate.

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

The combination of nilutamide and orchidectomy has a beneficial effect on pain of metastatic origin, levels of tumour markers, the objective response of disease and the time to disease progression, and this treatment combination might also improve survival.

Antiandrogens in the treatment of prostatic cancer.

It is emphasized that not only is CPA of great value in the treatment of prostatic carcinoma, but it is also useful in determining the hormone dependency of the tumor which is indispensable before proceeding with hormone therapy.

Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.

Results of this study suggest that Anandron may be a safe and effective treatment for patients with advanced prostatic cancer.